AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)
FDA Has Issued New Postmarketing Requirement
LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval
Related news for (AMGN)
- AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
- AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
- AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
- AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
- AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND